# Andreas von Deimling

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 673 papers | 66,529 citations | 115 h-index | 240 g-index |
| 735 ext. papers | 82,965 ext. citations | 8.4 avg, IF | 7.47 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 673 | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.. *Acta Neuropathologica Communications*, **2022**, 10, 5 | 7.3 | 2 |
| 672 | Prognostic impact of genetic alterations and methylation classes in meningioma.. *Brain Pathology*, **2022**, 32, e12970 | 6 | 2 |
| 671 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. *Acta Neuropathologica Communications*, **2022**, 10, 39 | 7.3 | 1 |
| 670 | Rapid-CNS: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.. *Acta Neuropathologica*, **2022**, 1 | 14.3 | 0 |
| 669 | Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.. *Journal of Pathology*, **2022**, | 9.4 | 1 |
| 668 | Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.. *Neuro-Oncology*, **2022**, | 1 | 1 |
| 667 | Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA.. *European Journal of Cancer*, **2022**, 168, 1-11 | 7.5 | 2 |
| 666 | OTHR-41. Amplification of the PLAG family genes PLAGL1 and PLAGL2 is a key feature of a novel embryonal CNS tumor type. *Neuro-Oncology*, **2022**, 24, i156-i156 | 1 | 0 |
| 665 | MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107 | 1 | |
| 664 | OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. *Neuro-Oncology*, **2022**, 24, i154-i154 | 1 | |
| 663 | LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. *Neuro-Oncology*, **2022**, 24, i91-i91 | 1 | |
| 662 | LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. *Neuro-Oncology*, **2022**, 24, i91-i92 | 1 | |
| 661 | LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. *Neuro-Oncology*, **2022**, 24, i90-i90 | 1 | |
| 660 | MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy Results of the MET-HIT2000-BIS4 trial. *Neuro-Oncology*, **2022**, 24, i104-i104 | 1 | |
| 659 | PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. *Neuro-Oncology*, **2021**, 23, vi119-vi120 | 1 | |
| 658 | NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA. *Neuro-Oncology*, **2021**, 23, vi157-vi157 | 1 | |
| 657 | PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. *Neuro-Oncology*, **2021**, 23, vi122-vi122 | 1 | |

| | | | |
|---|---|---|---|
| 656 | DNA methylation-based classification of malformations of cortical development in the human brain. *Acta Neuropathologica*, **2021**, 1 | 14.3 | 2 |
| 655 | Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. *Brain Pathology*, **2021**, e13037 | 6 | 0 |
| 654 | BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS. *Neuro-Oncology*, **2021**, 23, vi19-vi19 | 1 | |
| 653 | PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY. *Neuro-Oncology*, **2021**, 23, vi126-vi126 | 1 | |
| 652 | PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. *Neuro-Oncology*, **2021**, 23, vi123-vi124 | 1 | |
| 651 | Genetic and epigenetic characterization of posterior pituitary tumors. *Acta Neuropathologica*, **2021**, 142, 1025-1043 | 14.3 | 1 |
| 650 | Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. *Cancer*, **2021**, | 6.4 | 2 |
| 649 | Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *Journal of Clinical Oncology*, **2021**, 39, 3839-3852 | 2.2 | 8 |
| 648 | Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. *Acta Neuropathologica*, **2021**, 141, 281-290 | 14.3 | 9 |
| 647 | The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. *Neurosurgical Review*, **2021**, 44, 2707-2715 | 3.9 | 3 |
| 646 | The age of adult pilocytic astrocytoma cells. *Oncogene*, **2021**, 40, 2830-2841 | 9.2 | 2 |
| 645 | A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature*, **2021**, 592, 463-468 | 50.4 | 68 |
| 644 | Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. *European Journal of Cancer*, **2021**, 147, 84-94 | 7.5 | 3 |
| 643 | Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. *Journal of Neurochemistry*, **2021**, 158, 522-538 | 6 | 1 |
| 642 | Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. *Acta Neuropathologica*, **2021**, 141, 971-974 | 14.3 | 2 |
| 641 | Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. *Acta Neuropathologica*, **2021**, 142, 179-189 | 14.3 | 5 |
| 640 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. *Neuro-Oncology*, **2021**, 23, 1547-1559 | 1 | 7 |
| 639 | Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. *Cancer Discovery*, **2021**, 11, 2230-2247 | 24.4 | 20 |

| | | | |
|---|---|---|---|
| 638 | Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. *Modern Pathology*, **2021**, 34, 1558-1569 | 9.8 | 5 |
| 637 | Deep Neural Network for Differentiation of Brain Tumor Tissue Displayed by Confocal Laser Endomicroscopy. *Frontiers in Oncology*, **2021**, 11, 668273 | 5.3 | 2 |
| 636 | Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.. *Nature Cancer*, **2021**, 2, 723-740 | 15.4 | 17 |
| 635 | Loss of H3K27me3 in meningiomas. *Neuro-Oncology*, **2021**, 23, 1282-1291 | 1 | 7 |
| 634 | DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the 'DKFZ Sarcoma Classifier'. *Journal of Pathology: Clinical Research*, **2021**, 7, 350-360 | 5.3 | 3 |
| 633 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* , **2021**, 23, 1231-1251 | 1 | 708 |
| 632 | EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. *Neuro-Oncology*, **2021**, 23, i10-i10 | 1 | 78 |
| 631 | Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. *Modern Pathology*, **2021**, 34, 2043-2049 | 9.8 | 2 |
| 630 | Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel-Lindau disease-related tumours. *Neuropathology and Applied Neurobiology*, **2021**, 47, 756-767 | 5.2 | 0 |
| 629 | Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. *Neuro-Oncology*, **2021**, 23, 1597-1611 | 1 | 3 |
| 628 | EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. *Neuro-Oncology*, **2021**, 23, i47-i48 | 1 | 78 |
| 627 | EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. *Neuro-Oncology*, **2021**, 23, i13-i14 | 1 | 78 |
| 626 | Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. *Cancers*, **2021**, 13, | 6.6 | 2 |
| 625 | Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. *Journal of Nuclear Medicine*, **2021**, | 8.9 | 11 |
| 624 | Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. *Modern Pathology*, **2021**, 34, 2122-2129 | 9.8 | 4 |
| 623 | The molecular evolution of glioblastoma treated by gross total resection alone. *Neuro-Oncology*, **2021**, 23, 334-336 | 1 | 1 |
| 622 | Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. *Acta Neuropathologica*, **2021**, 141, 85-100 | 14.3 | 14 |
| 621 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature Reviews Clinical Oncology*, **2021**, 18, 170-186 | 19.4 | 204 |

| | | | |
|---|---|---|---|
| 620 | Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. *Neuropathology and Applied Neurobiology*, **2021**, 47, 406-414 | 5.2 | 2 |
| 619 | A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. *Neuro-Oncology*, **2021**, 23, 34-43 | 1 | 22 |
| 618 | Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. *Gut*, **2021**, | 19.2 | 4 |
| 617 | Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. *Acta Neuropathologica Communications*, **2021**, 9, 20 | 7.3 | 2 |
| 616 | Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. *Neuro-Oncology*, **2021**, 23, 1576-1585 | 1 | 3 |
| 615 | G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. *Cell*, **2021**, 184, 655-674.e27 | 36.2 | 13 |
| 614 | Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. *Nature Communications*, **2021**, 12, 1014 | 17.4 | 21 |
| 613 | Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation. *Radiotherapy and Oncology*, **2021**, 160, 192-201 | 5.3 | 10 |
| 612 | Molecular diagnostics in drug-resistant focal epilepsy define new disease entities. *Brain Pathology*, **2021**, 31, e12963 | 6 | 1 |
| 611 | DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. *Journal of Molecular Diagnostics*, **2021**, 23, 834-846 | 5.1 | 1 |
| 610 | Intrathecal activation of CD8 memory T cells in IgG4-related disease of the brain parenchyma. *EMBO Molecular Medicine*, **2021**, 13, e13953 | 12 | 1 |
| 609 | PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathologica*, **2021**, 142, 841-857 | 14.3 | 7 |
| 608 | Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839 | 14.3 | 5 |
| 607 | The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. *Cancer Discovery*, **2021**, 11, 2764-2779 | 24.4 | 22 |
| 606 | Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871 | 14.3 | 2 |
| 605 | Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. *Journal of Pathology*, **2021**, | 9.4 | 2 |
| 604 | Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. *Neuro-Oncology*, **2021**, | 1 | 4 |
| 603 | Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. *Nature Communications*, **2021**, 12, 5530 | 17.4 | 3 |

| | | | |
|---|---|---|---|
| 602 | Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes. *Neuro-Oncology Advances*, **2021**, 3, vdab147 | 0.9 | 0 |
| 601 | GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. *Acta Neuropathologica*, **2021**, 142, 1065-1069 | 14.3 | 1 |
| 600 | Sarcoma classification by DNA methylation profiling. *Nature Communications*, **2021**, 12, 498 | 17.4 | 74 |
| 599 | Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. *Theranostics*, **2021**, 11, 9217-9233 | 12.1 | 1 |
| 598 | PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. *Neuro-Oncology*, **2021**, 23, vi125-vi126 | 1 | |
| 597 | A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. *Cancer Discovery*, **2021**, | 24.4 | 5 |
| 596 | Oligosarcomas, IDH-mutant are distinct and aggressive.. *Acta Neuropathologica*, **2021**, 143, 263 | 14.3 | 0 |
| 595 | Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of. *JCO Precision Oncology*, **2020**, 4, | 3.6 | 0 |
| 594 | An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. *Acta Neuropathologica*, **2020**, 140, 237-239 | 14.3 | 3 |
| 593 | Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. *Neuro-Oncology*, **2020**, 22, 1667-1676 | 1 | 4 |
| 592 | Germline SDHB-inactivating mutation in gastric spindle cell sarcoma. *Genes Chromosomes and Cancer*, **2020**, 59, 601-608 | 5 | 2 |
| 591 | Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. *Cancers*, **2020**, 12, | 6.6 | 4 |
| 590 | CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathologica*, **2020**, 140, 409-413 | 14.3 | 26 |
| 589 | Molecular profiling-based decision for targeted therapies in wild-type glioblastoma. *Neuro-Oncology Advances*, **2020**, 2, vdz060 | 0.9 | 2 |
| 588 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. *Neuro-Oncology*, **2020**, 22, 1162-1172 | 1 | 22 |
| 587 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. *Nature Communications*, **2020**, 11, 931 | 17.4 | 57 |
| 586 | Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. *Langenbeckls Archives of Surgery*, **2020**, 405, 199-205 | 3.4 | 3 |
| 585 | Analysis of a Surgical Series of 21 Cerebral Radiation Necroses. *World Neurosurgery*, **2020**, 137, e462-e469 | 2.1 | 2 |

| | | | |
|---|---|---|---|
| 584 | Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. *Clinical Cancer Research*, **2020**, 26, 2231-2243 | 12.9 | 7 |
| 583 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathologica*, **2020**, 139, 603-608 | 14.3 | 170 |
| 582 | Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. *Journal of Pathology: Clinical Research*, **2020**, 6, 178-184 | 5.3 | 10 |
| 581 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro-Oncology*, **2020**, 22, 1073-1113 | 1 | 178 |
| 580 | Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. *Journal of Clinical Oncology*, **2020**, 38, 2028-2040 | 2.2 | 21 |
| 579 | Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. *Journal of Clinical Investigation*, **2020**, 130, 2488-2495 | 15.9 | 8 |
| 578 | The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. *Journal of Clinical Oncology*, **2020**, 38, LBA10503-LBA10503 | 2.2 | 9 |
| 577 | Quality assurance in neuropathology: Experiences from the round robin trials on mutation and promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019 **2020**, 39, 203-211 | | 3 |
| 576 | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA RESULTS OF THE HIT2000 TRIAL. *Neuro-Oncology*, **2020**, 22, iii433-iii433 | 1 | 78 |
| 575 | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS. *Neuro-Oncology*, **2020**, 22, iii413-iii413 | 1 | 78 |
| 574 | PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS. *Neuro-Oncology*, **2020**, 22, iii425-iii425 | 1 | 78 |
| 573 | PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS. *Neuro-Oncology*, **2020**, 22, iii429-iii430 | 1 | 78 |
| 572 | LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE. *Neuro-Oncology*, **2020**, 22, iii372-iii373 | 1 | 78 |
| 571 | EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. *Neuro-Oncology*, **2020**, 22, iii311-iii311 | 1 | 78 |
| 570 | MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. *Neuro-Oncology*, **2020**, 22, iii388-iii388 | 1 | 78 |
| 569 | MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). *Neuro-Oncology*, **2020**, 22, iii410-iii410 | 1 | 78 |
| 568 | PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS THE MNP 2.0 STUDY. *Neuro-Oncology*, **2020**, 22, iii426-iii426 | 1 | 78 |
| 567 | Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. *Acta Neuropathologica*, **2020**, 139, 403-406 | 14.3 | 6 |

| | | | |
|---|---|---|---|
| 566 | T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. *Neuro-Oncology Advances*, **2020**, 2, vdaa004 | 0.9 | 14 |
| 565 | Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. *Nature Protocols*, **2020**, 15, 479-512 | 18.8 | 34 |
| 564 | Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. *Acta Neuropathologica*, **2020**, 139, 277-286 | 14.3 | 12 |
| 563 | YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218 | 14.3 | 24 |
| 562 | DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. *The Lancet Child and Adolescent Health*, **2020**, 4, 121-130 | 14.5 | 21 |
| 561 | Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. *Brain Pathology*, **2020**, 30, 213-225 | 6 | 14 |
| 560 | Kaposiform hemangioendothelioma and tufted angioma - (epi)genetic analysis including genome-wide methylation profiling. *Annals of Diagnostic Pathology*, **2020**, 44, 151434 | 2.2 | 6 |
| 559 | Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. *Acta Neuropathologica*, **2020**, 139, 243-257 | 14.3 | 20 |
| 558 | High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. *Pathology Research and Practice*, **2020**, 216, 152728 | 3.4 | 3 |
| 557 | Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. *Acta Neuropathologica*, **2020**, 139, 583-596 | 14.3 | 6 |
| 556 | DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 97-104 | 4.9 | 19 |
| 555 | IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, **2020**, 182, 1252-1270.e34 | 56.2 | 84 |
| 554 | Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. *Acta Neuropathologica*, **2020**, 140, 881-891 | 14.3 | 10 |
| 553 | Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. *Cancer Medicine*, **2020**, 9, 8373-8385 | 4.8 | 7 |
| 552 | An activating germline variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid.. *Human Genetics and Genomics Advances*, **2020**, 1, 100006 | 0.8 | 1 |
| 551 | Infratentorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathologica*, **2020**, 140, 569-581 | 14.3 | 17 |
| 550 | Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. *Radiology*, **2020**, 297, 164-175 | 20.5 | 7 |
| 549 | Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. *Acta Neurochirurgica*, **2020**, 162, 3019-3024 | 3 | 2 |

| | | | |
|---|---|---|---|
| 548 | Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. *Translational Oncology*, **2020**, 13, 100852 | 4.9 | 1 |
| 547 | Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. *Acta Neuropathologica*, **2020**, 140, 893-906 | 14.3 | 10 |
| 546 | DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. *Clinical Cancer Research*, **2020**, 26, 93-100 | 12.9 | 18 |
| 545 | Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. *Acta Neuropathologica*, **2020**, 139, 193-209 | 14.3 | 35 |
| 544 | Assessment of Melanin Content and its Influence on Susceptibility Contrast in Melanoma Metastases. *Clinical Neuroradiology*, **2020**, 30, 607-614 | 2.7 | 2 |
| 543 | Sclerosing epithelioid mesenchymal neoplasm of the pancreas□□a proposed new entity. *Modern Pathology*, **2020**, 33, 456-467 | 9.8 | 5 |
| 542 | FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. *Acta Neuropathologica*, **2020**, 139, 175-192 | 14.3 | 4 |
| 541 | cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathology*, **2020**, 30, 844-856 | 6 | 196 |
| 540 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. *Cancer Discovery*, **2020**, 10, 942-963 | 24.4 | 65 |
| 539 | Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathologica Communications*, **2019**, 7, 163 | 7.3 | 18 |
| 538 | Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 1073-1075 | 3.1 | 4 |
| 537 | Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. *Acta Neuropathologica Communications*, **2019**, 7, 140 | 7.3 | 13 |
| 536 | Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. *Cancers*, **2019**, 11, | 6.6 | 11 |
| 535 | Targeted Genomic Profiling of Acral Melanoma. *Journal of the National Cancer Institute*, **2019**, 111, 1068-1077 | 9.7 | 55 |
| 534 | Advances in multidisciplinary therapy for meningiomas. *Neuro-Oncology*, **2019**, 21, i18-i31 | 1 | 44 |
| 533 | Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. *Clinical Cancer Research*, **2019**, 25, 5260-5270 | 12.9 | 7 |
| 532 | Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. *Acta Neuropathologica*, **2019**, 138, 497-504 | 14.3 | 36 |
| 531 | DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. *Neuro-Oncology*, **2019**, 21, 901-910 | 1 | 79 |

| | | | |
|---|---|---|---|
| 530 | GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. *Neuro-Oncology*, **2019**, 21, ii82-ii82 | 1 | 1 |
| 529 | Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. *Annals of Diagnostic Pathology*, **2019**, 41, 102-105 | 2.2 | 5 |
| 528 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Molecular and Cellular Proteomics*, **2019**, 18, 1255-1268 | 7.6 | 26 |
| 527 | Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathologica*, **2019**, 138, 295-308 | 14.3 | 27 |
| 526 | GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. *Neuro-Oncology*, **2019**, 21, ii83-ii83 | 1 | 0 |
| 525 | RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. *Acta Neuropathologica*, **2019**, 138, 275-293 | 14.3 | 2 |
| 524 | Impact of post-surgical freezing delay on brain tumor metabolomics. *Metabolomics*, **2019**, 15, 78 | 4.7 | 3 |
| 523 | Identification of KIF11 As a Novel Target in Meningioma. *Cancers*, **2019**, 11, | 6.6 | 17 |
| 522 | GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. *Neuro-Oncology*, **2019**, 21, ii81-ii82 | 1 | 78 |
| 521 | LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. *Neuro-Oncology*, **2019**, 21, ii101-ii102 | 1 | 78 |
| 520 | Molecular progression of SHH-activated medulloblastomas. *Acta Neuropathologica*, **2019**, 138, 327-330 | 14.3 | 2 |
| 519 | Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. *Neurosurgery*, **2019**, 85, E722-E729 | 3.2 | 8 |
| 518 | DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1273-1281 | 4.9 | 29 |
| 517 | Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. *Acta Neuropathologica Communications*, **2019**, 7, 24 | 7.3 | 49 |
| 516 | Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. *Clinical Sarcoma Research*, **2019**, 9, 2 | 2.5 | 25 |
| 515 | Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. *Cancer Cell*, **2019**, 35, 692-704.e12 | 24.3 | 92 |
| 514 | Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. *Lancet Oncology, The*, **2019**, 20, 728-740 | 21.7 | 160 |
| 513 | Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. *Acta Neuropathologica*, **2019**, 137, 847-850 | 14.3 | 2 |

| | | | |
|---|---|---|---|
| 512 | CIC protein instability contributes to tumorigenesis in glioblastoma. *Nature Communications*, **2019**, 10, 661 | 17.4 | 39 |
| 511 | IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2569-2580 | 8.8 | 50 |
| 510 | Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. *Cancer Research*, **2019**, 79, 4994-5007 | 10.1 | 21 |
| 509 | MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089 | 14.3 | 51 |
| 508 | Incidence, mortality and outcome of meningiomas: A population-based study from Germany. *Cancer Epidemiology*, **2019**, 62, 101562 | 2.8 | 39 |
| 507 | Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. *Cancers*, **2019**, 11, | 6.6 | 7 |
| 506 | Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. *Acta Neuropathologica*, **2019**, 138, 827-835 | 14.3 | 24 |
| 505 | Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. *Journal of Neuro-Oncology*, **2019**, 145, 469-477 | 4.8 | 15 |
| 504 | Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. *Letters in Drug Design and Discovery*, **2019**, 16, 861-867 | 0.8 | 2 |
| 503 | Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. *Journal of Clinical Oncology*, **2019**, 37, 2013-2013 | 2.2 | |
| 502 | Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. *Journal of Clinical Oncology*, **2019**, 37, 2057-2057 | 2.2 | 0 |
| 501 | Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. *Acta Neuropathologica*, **2019**, 137, 1003-1015 | 14.3 | 2 |
| 500 | Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathologica*, **2019**, 137, 837-846 | 14.3 | 28 |
| 499 | Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. *Acta Neuropathologica Communications*, **2019**, 7, 201 | 7.3 | 5 |
| 498 | The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280 | 50.4 | 46 |
| 497 | Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature*, **2019**, 565, 240-245 | 50.4 | 388 |
| 496 | Ectopic intracranial retinoblastoma in a 3.5-month-old infant without eye involvement and without evidence of heritability. *Pediatric Blood and Cancer*, **2019**, 66, e27599 | 3 | 3 |
| 495 | Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. *Neuro-Oncology*, **2019**, 21, i32-i43 | 1 | 33 |

| | | | |
|---|---|---|---|
| 494 | Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. *International Journal of Cancer*, **2019**, 145, 461-473 | 7.5 | 3 |
| 493 | Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathologica*, **2019**, 137, 521-525 | 14.3 | 24 |
| 492 | Imaging and diagnostic advances for intracranial meningiomas. *Neuro-Oncology*, **2019**, 21, i44-i61 | 1 | 55 |
| 491 | Molecular and translational advances in meningiomas. *Neuro-Oncology*, **2019**, 21, i4-i17 | 1 | 46 |
| 490 | The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. *Clinical Cancer Research*, **2019**, 25, 1851-1866 | 12.9 | 26 |
| 489 | DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. *Neuro-Oncology*, **2019**, 21, 214-221 | 1 | 13 |
| 488 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro-Oncology*, **2019**, 21, 95-105 | 1 | 55 |
| 487 | Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. *Clinical Cancer Research*, **2019**, 25, 253-265 | 12.9 | 23 |
| 486 | Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. *Frontiers in Neuroscience*, **2018**, 12, 1004 | 5.1 | 10 |
| 485 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166 | 14.3 | 162 |
| 484 | Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. *Acta Neuropathologica*, **2018**, 135, 955-963 | 14.3 | 61 |
| 483 | Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. *Molecular Cancer Research*, **2018**, 16, 767-776 | 6.6 | 14 |
| 482 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. *Acta Neuropathologica*, **2018**, 135, 601-615 | 14.3 | 54 |
| 481 | IDH1 mutant glioma initiating cells are predisposed to apoptosis under endoplasmic reticulum (ER) stress. *Neuro-Oncology*, **2018**, 20, i13-i13 | 1 | 1 |
| 480 | Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 422-425 | 3.1 | 38 |
| 479 | Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. *Neuro-Oncology*, **2018**, 20, 826-837 | 1 | 27 |
| 478 | Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 388-393 | 2.9 | 7 |
| 477 | Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. *Acta Neuropathologica Communications*, **2018**, 6, 21 | 7.3 | 21 |

| | | | |
|---|---|---|---|
| 476 | DNA methylation-based reclassification of olfactory neuroblastoma. *Acta Neuropathologica*, **2018**, 136, 255-271 | 14.3 | 35 |
| 475 | DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474 | 50.4 | 992 |
| 474 | A PRDX1-p38 heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. *International Journal of Cancer*, **2018**, 143, 1176-1187 | 7.5 | 10 |
| 473 | Extra-small dual-lumen micro-balloon catheters can improve endovascular embolization: an experimental in vivo and in vitro study. *Journal of NeuroInterventional Surgery*, **2018**, 10, 1092-1096 | 7.8 | 12 |
| 472 | Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. *Acta Neuropathologica*, **2018**, 136, 273-291 | 14.3 | 99 |
| 471 | Molecular characterization of medulloblastomas with extensive nodularity (MBEN). *Acta Neuropathologica*, **2018**, 136, 303-313 | 14.3 | 9 |
| 470 | Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. *Clinical Cancer Research*, **2018**, 24, 2951-2962 | 12.9 | 21 |
| 469 | Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. *Modern Pathology*, **2018**, 31, 1246-1256 | 9.8 | 58 |
| 468 | Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. *Seminars in Neurology*, **2018**, 38, 19-23 | 3.2 | 18 |
| 467 | Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. *Journal of Neurosurgery*, **2018**, 128, 1102-1114 | 3.2 | 16 |
| 466 | Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model. *Journal of NeuroInterventional Surgery*, **2018**, 10, 268-274 | 7.8 | 22 |
| 465 | Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. *Neuro-Oncology*, **2018**, 20, 848-857 | 1 | 111 |
| 464 | Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. *Brain Pathology*, **2018**, 28, 656-662 | 6 | 65 |
| 463 | Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. *Neuro-Oncology*, **2018**, 20, 367-379 | 1 | 35 |
| 462 | Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. *Modern Pathology*, **2018**, 31, 160-168 | 9.8 | 3 |
| 461 | EGFL7 enhances surface expression of integrin to promote angiogenesis in malignant brain tumors. *EMBO Molecular Medicine*, **2018**, 10, | 12 | 24 |
| 460 | DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. *Neuro-Oncology*, **2018**, 20, 1616-1624 | 1 | 32 |
| 459 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Molecular and Cellular Proteomics*, **2018**, 17, 2132-2145 | 7.6 | 16 |

| | | | |
|---|---|---|---|
| 458 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nature Medicine*, **2018**, 24, 1192-1203 | 50.5 | 174 |
| 457 | BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. *Journal of Investigative Dermatology*, **2018**, 138, 2489-2491 | 4.3 | 3 |
| 456 | Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series. *Klinische Padiatrie*, **2018**, 230, 305-313 | 0.9 | 4 |
| 455 | Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1573-1584 | 8.8 | 14 |
| 454 | Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. *Neuro-Oncology*, **2018**, 20, 1517-1524 | 1 | 24 |
| 453 | Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. *Acta Neuropathologica*, **2018**, 136, 327-337 | 14.3 | 63 |
| 452 | Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. *Clinical Cancer Research*, **2018**, 24, 4494-4504 | 12.9 | 14 |
| 451 | LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES. *Neuro-Oncology*, **2018**, 20, i108-i108 | 1 | 78 |
| 450 | GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2000-2000 | 2.2 | 8 |
| 449 | A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. *Journal of Clinical Oncology*, **2018**, 36, 2001-2001 | 2.2 | 15 |
| 448 | VXM01 phase I study in patients with progressive glioblastoma: Final results.. *Journal of Clinical Oncology*, **2018**, 36, 2017-2017 | 2.2 | 3 |
| 447 | Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2013-2013 | 2.2 | |
| 446 | Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases.. *Journal of Clinical Oncology*, **2018**, 36, e21515-e21515 | 2.2 | |
| 445 | Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. *Journal of Clinical Oncology*, **2018**, 36, 12090-12090 | 2.2 | |
| 444 | IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. *Neuro-Oncology*, **2018**, 20, vi133-vi133 | 1 | 78 |
| 443 | Proteomics in Pathology. *Proteomics*, **2018**, 18, 1700361 | 4.8 | 14 |
| 442 | TBIO-10. PEDIATRIC TARGETED THERAPY 2.0: DEVELOPMENT OF PERSONALIZED PEDIATRIC ONCOLOGY. *Neuro-Oncology*, **2018**, 20, i182-i182 | 1 | 78 |
| 441 | Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. *Journal of Clinical Oncology*, **2018**, JCO2017764720 | 2.2 | 34 |

| | | | |
|---|---|---|---|
| 440 | CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi48-vi49 | 1 | 78 |
| 439 | LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2018**, 20, i106-i106 | 1 | 78 |
| 438 | TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICS□THE PROSPECTIVE MNP2.0 STUDY. *Neuro-Oncology*, **2018**, 20, i181-i181 | 1 | 78 |
| 437 | cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathologica*, **2018**, 136, 805-810 | 14.3 | 367 |
| 436 | Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures. *PLoS ONE*, **2018**, 13, e0205772 | 3.7 | 5 |
| 435 | Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 1472-1480 | 4 | 4 |
| 434 | Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. *Acta Neuropathologica*, **2018**, 136, 975-978 | 14.3 | 5 |
| 433 | Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathologica*, **2018**, 136, 793-803 | 14.3 | 102 |
| 432 | Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. *Journal of Neuro-Oncology*, **2018**, 140, 659-667 | 4.8 | 7 |
| 431 | Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. *European Journal of Radiology*, **2018**, 105, 119-124 | 4.7 | 17 |
| 430 | Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. *Journal of Medicinal Chemistry*, **2018**, 61, 8981-9003 | 8.3 | 14 |
| 429 | Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. *Acta Neuropathologica*, **2018**, 136, 239-253 | 14.3 | 73 |
| 428 | FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. *Acta Neuropathologica*, **2018**, 136, 293-302 | 14.3 | 29 |
| 427 | MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY. *Neuro-Oncology*, **2018**, 20, i121-i121 | 1 | 78 |
| 426 | Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. *Acta Neuropathologica*, **2018**, 136, 181-210 | 14.3 | 148 |
| 425 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. *Acta Neuropathologica*, **2017**, 133, 629-644 | 14.3 | 115 |
| 424 | H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. *Acta Neuropathologica*, **2017**, 134, 507-516 | 14.3 | 70 |
| 423 | Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. *Acta Neuropathologica*, **2017**, 134, 155-158 | 14.3 | 19 |

| | | | |
|---|---|---|---|
| 422 | Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. *Acta Neuropathologica Communications*, **2017**, 5, 39 | 7.3 | 65 |
| 421 | Diagnostic challenges in meningioma. *Neuro-Oncology*, **2017**, 19, 1588-1598 | 1 | 57 |
| 420 | Tweety-Homolog 1 Drives Brain Colonization of Gliomas. *Journal of Neuroscience*, **2017**, 37, 6837-6850 | 6.6 | 62 |
| 419 | Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. *Acta Neuropathologica*, **2017**, 134, 297-316 | 14.3 | 17 |
| 418 | DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncology, The*, **2017**, 18, 682-694 | 21.7 | 336 |
| 417 | Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. *Experimental and Molecular Pathology*, **2017**, 102, 25-31 | 4.4 | 8 |
| 416 | Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. *Acta Neuropathologica*, **2017**, 133, 325-327 | 14.3 | 10 |
| 415 | Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. *Molecular Therapy*, **2017**, 25, 2620-2634 | 11.7 | 130 |
| 414 | DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. *Acta Neuropathologica*, **2017**, 134, 965-967 | 14.3 | 20 |
| 413 | Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 6379-6387 | 3.4 | 3 |
| 412 | Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 997-999 | 3.1 | |
| 411 | PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. *Neuro-Oncology*, **2017**, 19, vi184-vi185 | 1 | 2 |
| 410 | LGG-04. CHARACTERIZATION OF ONCOGENE-INDUCED SENESCENCE AND THE ROLE OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2017**, 19, iv33-iv33 | 1 | 78 |
| 409 | TRTH-09. PTT2.0: DEVELOPING PERSONALIZED PEDIATRIC ONCOLOGY. *Neuro-Oncology*, **2017**, 19, iv53-iv53 | 1 | 78 |
| 408 | ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2017**, 19, vi2-vi2 | 1 | 3 |
| 407 | Loss of Mpdz impairs ependymal cell integrity leading to perinatal-onset hydrocephalus in mice. *EMBO Molecular Medicine*, **2017**, 9, 890-905 | 12 | 31 |
| 406 | Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. *Clinical Cancer Research*, **2017**, 23, 6846-6855 | 12.9 | 94 |
| 405 | The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317 | 50.4 | 472 |

| | | | |
|---|---|---|---|
| 404 | Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. *Nature Communications*, **2017**, 8, 186 | 17.4 | 45 |
| 403 | GENE-07. MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. *Neuro-Oncology*, **2017**, 19, iv19-iv19 | 1 | 78 |
| 402 | Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO and Shakespeare. *Acta Neuropathologica*, **2017**, 134, 517-520 | 14.3 | 9 |
| 401 | Lomustine and Bevacizumab in Progressive Glioblastoma. *New England Journal of Medicine*, **2017**, 377, 1954-1963 | 59.2 | 425 |
| 400 | Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 655-664 | 2.1 | 9 |
| 399 | Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. *Journal of the National Cancer Institute*, **2017**, 109, 1-4 | 9.7 | 31 |
| 398 | Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. *Clinical Sarcoma Research*, **2017**, 7, 9 | 2.5 | 30 |
| 397 | K27M-mutant histone-3 as a novel target for glioma immunotherapy. *OncoImmunology*, **2017**, 6, e1328340 | 7.2 | 47 |
| 396 | cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017**, 27, 851-852 | 6 | 36 |
| 395 | The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. *Acta Neuropathologica*, **2017**, 133, 5-12 | 14.3 | 202 |
| 394 | MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE?. *Neuro-Oncology*, **2017**, 19, vi132-vi132 | 1 | 78 |
| 393 | NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101. *Neuro-Oncology*, **2017**, 19, vi153-vi153 | 1 | 78 |
| 392 | PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. *Neuro-Oncology*, **2017**, 19, vi175-vi176 | 1 | 78 |
| 391 | PDTM-47. CHARACTERIZATION OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA AND ITS ROLE IN ONCOGENE-INDUCED SENESCENCE. *Neuro-Oncology*, **2017**, 19, vi200-vi200 | 1 | 78 |
| 390 | Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. *International Journal of Molecular Sciences*, **2017**, 18, | 6.3 | 20 |
| 389 | The INFORM personalized medicine study for high-risk pediatric cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 10509-10509 | 2.2 | 0 |
| 388 | VXM01 phase I study in patients with resectable progression of a glioblastoma.. *Journal of Clinical Oncology*, **2017**, 35, 2061-2061 | 2.2 | 2 |
| 387 | -associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. *Cell Stress*, **2017**, 1, 55-67 | 5.5 | 3 |

| | | | |
|---|---|---|---|
| 386 | Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. *Oncotarget*, **2017**, 8, 11460-11479 | 3.3 | 28 |
| 385 | Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.. *Journal of Clinical Oncology*, **2017**, 35, 2013-2013 | 2.2 | |
| 384 | Gliomatosis cerebri: no evidence for a separate brain tumor entity. *Acta Neuropathologica*, **2016**, 131, 309-319 | 14.3 | 59 |
| 383 | Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. *Acta Neuropathologica*, **2016**, 131, 137-46 | 14.3 | 102 |
| 382 | Evidence of H3 K27M mutations in posterior fossa ependymomas. *Acta Neuropathologica*, **2016**, 132, 635-7 | 14.3 | 55 |
| 381 | Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. *Radiology*, **2016**, 281, 907-918 | 20.5 | 177 |
| 380 | Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. *BMC Cancer*, **2016**, 16, 81 | 4.8 | 30 |
| 379 | Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. *Acta Neuropathologica Communications*, **2016**, 4, 20 | 7.3 | 101 |
| 378 | Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. *Journal of Neuro-Oncology*, **2016**, 129, 319-28 | 4.8 | 20 |
| 377 | Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. *Acta Neuropathologica*, **2016**, 131, 903-10 | 14.3 | 151 |
| 376 | Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2016**, 131, 877-87 | 14.3 | 110 |
| 375 | Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. *Clinical Neurology and Neurosurgery*, **2016**, 142, 72-80 | 2 | 18 |
| 374 | Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro-Oncology*, **2016**, 18, 790-6 | 1 | 46 |
| 373 | Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393 | 24.3 | 319 |
| 372 | New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072 | 36.2 | 483 |
| 371 | TERT Promoter Mutations and Risk of Recurrence in Meningioma. *Journal of the National Cancer Institute*, **2016**, 108, | 9.7 | 189 |
| 370 | Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. *Blood*, **2016**, 128, 745-745 | 2.2 | 7 |
| 369 | EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. *Journal of Clinical Oncology*, **2016**, 34, 2042-2042 | 2.2 | 3 |

| | | | |
|---|---|---|---|
| 368 | A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. *Journal of Clinical Oncology*, **2016**, 34, TPS2082-TPS2082 | 2.2 | 5 |
| 367 | Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N□M□).. *Journal of Clinical Oncology*, **2016**, 34, TPS2084-TPS2084 | 2.2 | 4 |
| 366 | MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. *Oncotarget*, **2016**, 7, 66344-66359 | 3.3 | 21 |
| 365 | Prognostic relevance of miRNA-155 methylation in anaplastic glioma. *Oncotarget*, **2016**, 7, 82028-82045 | 3.3 | 15 |
| 364 | Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. *Oncotarget*, **2016**, 7, 14551-68 | 3.3 | 26 |
| 363 | Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. *Oncotarget*, **2016**, 7, 23006-18 | 3.3 | 4 |
| 362 | LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. *Neuro-Oncology*, **2016**, 18, iii84.3-iii84 | 1 | 78 |
| 361 | TB-11MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. *Neuro-Oncology*, **2016**, 18, iii170.4-iii170 | 1 | 78 |
| 360 | TB-14THE INFORM PERSONALIZED MEDICINE STUDY - NEW MOLECULAR INSIGHTS INTO RELAPSED PEDIATRIC BRAIN TUMORS. *Neuro-Oncology*, **2016**, 18, iii171.1-iii171 | 1 | 78 |
| 359 | Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. *Journal of Neurochemistry*, **2016**, 136, 1142-1154 | 6 | 37 |
| 358 | Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. *Brain Pathology*, **2016**, 26, 506-16 | 6 | 10 |
| 357 | LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. *International Journal of Cancer*, **2016**, 139, 424-32 | 7.5 | 13 |
| 356 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *Neuro-Oncology*, **2016**, 18, 1529-1537 | 1 | 80 |
| 355 | Differential nuclear ATRX expression in sarcomas. *Histopathology*, **2016**, 68, 738-45 | 7.3 | 15 |
| 354 | Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. *Brain Pathology*, **2016**, 26, 199-205 | 6 | 25 |
| 353 | RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy. *Autophagy*, **2016**, 12, 1413-5 | 10.2 | 4 |
| 352 | Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. *Genes Chromosomes and Cancer*, **2016**, 55, 418-27 | 5 | 29 |
| 351 | Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. *BMC Medicine*, **2016**, 14, 170 | 11.4 | 23 |

| | | | |
|---|---|---|---|
| 350 | IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. *Cancer Research*, **2016**, 76, 7118-7129 | 10.1 | 70 |
| 349 | Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. *Journal of Molecular Diagnostics*, **2016**, 18, 370-377 | 5.1 | 21 |
| 348 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. *Journal of Neuro-Oncology*, **2016**, 128, 341-8 | 4.8 | 21 |
| 347 | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, **2016**, 131, 803-20 | 14.3 | 8580 |
| 346 | EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncology, The*, **2016**, 17, e383-91 | 27.7 | 414 |
| 345 | Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. *RSC Advances*, **2016**, 6, 96735-96742 | 3.7 | 8 |
| 344 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncology, The*, **2016**, 17, 1521-1532 | 27.7 | 294 |
| 343 | HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2016**, 18, iii63.2-iii63 | 1 | 78 |
| 342 | Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *European Journal of Cancer*, **2016**, 65, 91-101 | 7.5 | 186 |
| 341 | Farewell to oligoastrocytoma: response to letters. *Acta Neuropathologica*, **2015**, 129, 155 | 14.3 | 7 |
| 340 | Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathologica*, **2015**, 129, 669-78 | 14.3 | 220 |
| 339 | Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathologica*, **2015**, 130, 407-17 | 14.3 | 194 |
| 338 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98 | 59.2 | 1828 |
| 337 | Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. *Acta Neuropathologica Communications*, **2015**, 3, 22 | 7.3 | 46 |
| 336 | Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathologica*, **2015**, 129, 679-93 | 14.3 | 208 |
| 335 | Glioblastoma: pathology, molecular mechanisms and markers. *Acta Neuropathologica*, **2015**, 129, 829-48 | 14.3 | 360 |
| 334 | Brain tumour cells interconnect to a functional and resistant network. *Nature*, **2015**, 528, 93-8 | 50.4 | 496 |
| 333 | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathologica*, **2015**, 129, 133-46 | 14.3 | 313 |

| | | | |
|---|---|---|---|
| 332 | BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 1596-602 | 2.4 | 75 |
| 331 | Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. *Glia*, **2015**, 63, 78-90 | 9 | 39 |
| 330 | ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. *Neuro-Oncology*, **2015**, 17, v42.3-v42 | 1 | 78 |
| 329 | Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 382-8 | 1.9 | 6 |
| 328 | IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. *Scientific Reports*, **2015**, 5, 16238 | 4.9 | 182 |
| 327 | SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS. *Neuro-Oncology*, **2015**, 17, v217.4-v217 | 1 | 78 |
| 326 | IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. *Neuro-Oncology*, **2015**, 17, v116.1-v116 | 1 | 1 |
| 325 | Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. *Neuropathology*, **2015**, 35, 538-44 | 2 | 29 |
| 324 | Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. *Glia*, **2015**, 63, 1850-9 | 9 | 11 |
| 323 | Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. *Oncotarget*, **2015**, 6, 13579-90 | 3.3 | 17 |
| 322 | Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43 | 24.3 | 672 |
| 321 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. *Journal of Neuro-Oncology* , **2015**, 124, 265-73 | 4.8 | 13 |
| 320 | Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. *Acta Neuropathologica*, **2015**, 130, 419-34 | 14.3 | 41 |
| 319 | IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. *Acta Neuropathologica*, **2015**, 129, 867-73 | 14.3 | 200 |
| 318 | Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. *Neuropathology and Applied Neurobiology*, **2015**, 41, 694-720 | 5.2 | 72 |
| 317 | Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. *Brain Pathology*, **2015**, 25, 202-8 | 6 | 54 |
| 316 | BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. *Neuropathology and Applied Neurobiology*, **2015**, 41, 733-42 | 5.2 | 40 |
| 315 | Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. *Modern Pathology*, **2015**, 28, 187-200 | 9.8 | 97 |

| | | | |
|---|---|---|---|
| 314 | Proximity ligation assay evaluates IDH1R132H presentation in gliomas. *Journal of Clinical Investigation*, **2015**, 125, 593-606 | 15.9 | 27 |
| 313 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. *Journal of Clinical Oncology*, **2015**, 33, 2001-2001 | 2.2 | 7 |
| 312 | Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. *Journal of Clinical Oncology*, **2015**, 33, 2006-2006 | 2.2 | 7 |
| 311 | Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. *Journal of Clinical Oncology*, **2015**, 33, 2007-2007 | 2.2 | 1 |
| 310 | Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. *Oncotarget*, **2015**, 6, 31050-68 | 3.3 | 35 |
| 309 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme.. *Journal of Clinical Oncology*, **2015**, 33, e13046-e13046 | 2.2 | |
| 308 | Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. *Acta Neuropathologica*, **2014**, 127, 565-72 | 14.3 | 33 |
| 307 | High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. *Lung Cancer*, **2014**, 83, 83-9 | 5.9 | 50 |
| 306 | Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. *International Journal of Cancer*, **2014**, 135, 1822-31 | 7.5 | 89 |
| 305 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405 | 24.3 | 469 |
| 304 | Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. *Thyroid*, **2014**, 24, 858-66 | 6.2 | 51 |
| 303 | Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. *Histopathology*, **2014**, 65, 613-22 | 7.3 | 83 |
| 302 | Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. *Neuro-Oncology*, **2014**, 16, 914-23 | 1 | 55 |
| 301 | BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. *Brain Pathology*, **2014**, 24, 221-9 | 6 | 61 |
| 300 | Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. *Journal of Pathology*, **2014**, 234, 23-33 | 9.4 | 39 |
| 299 | GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. *Cancer Research*, **2014**, 74, 2604-16 | 10.1 | 37 |
| 298 | Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*, **2014**, 128, 279-89 | 14.3 | 152 |
| 297 | Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer. *Histopathology*, **2014**, 65, 684-92 | 7.3 | 21 |

| | | | |
|---|---|---|---|
| 296 | Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. *Modern Pathology*, **2014**, 27, 135-44 | 9.8 | 39 |
| 295 | A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. *Clinical Cancer Research*, **2014**, 20, 6304-13 | 12.9 | 89 |
| 294 | International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathology*, **2014**, 24, 429-35 | 6 | 408 |
| 293 | Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathologica*, **2014**, 128, 449-52 | 14.3 | 28 |
| 292 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. *Journal of Experimental and Clinical Cancer Research*, **2014**, 33, 33 | 12.8 | 57 |
| 291 | D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. *Acta Neuropathologica Communications*, **2014**, 2, 19 | 7.3 | 57 |
| 290 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathologica*, **2014**, 128, 561-71 | 14.3 | 148 |
| 289 | Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathologica*, **2014**, 128, 551-9 | 14.3 | 200 |
| 288 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature*, **2014**, 511, 428-34 | 50.4 | 377 |
| 287 | A vaccine targeting mutant IDH1 induces antitumour immunity. *Nature*, **2014**, 512, 324-7 | 50.4 | 481 |
| 286 | MGMT testing--the challenges for biomarker-based glioma treatment. *Nature Reviews Neurology*, **2014**, 10, 372-85 | 15 | 316 |
| 285 | Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. *PLoS ONE*, **2014**, 9, e86194 | 3.7 | 35 |
| 284 | BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Modern Pathology*, **2014**, 27, 1028-34 | 9.8 | 72 |
| 283 | Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. *Archives of Pathology and Laboratory Medicine*, **2014**, 138, 71-5 | 5 | 46 |
| 282 | Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology*, **2014**, 16, 1630-8 | 7 | 59 |
| 281 | Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. *Acta Neuropathologica*, **2014**, 128, 879-91 | 14.3 | 46 |
| 280 | Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. *International Journal of Cancer*, **2014**, 134, 2437-47 | 7.5 | 73 |
| 279 | MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. *Archives of Dermatological Research*, **2014**, 306, 873-84 | 3.3 | 8 |

| | | | |
|---|---|---|---|
| 278 | mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 409-14 | 11.5 | 126 |
| 277 | Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. *Journal of Clinical Oncology*, **2014**, 32, 2006-2006 | 2.2 | 2 |
| 276 | Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. *Journal of Clinical Oncology*, **2014**, 32, 2014-2014 | 2.2 | 9 |
| 275 | Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. *Journal of Clinical Oncology*, **2014**, 32, 2017-2017 | 2.2 | 3 |
| 274 | Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. *Oncotarget*, **2014**, 5, 1038-51 | 3.3 | 189 |
| 273 | Interlaboratory comparison of IDH mutation detection. *Journal of Neuro-Oncology*, **2013**, 112, 173-8 | 4.8 | 54 |
| 272 | Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32 | 36.3 | 550 |
| 271 | Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and □KG. *Acta Neuropathologica Communications*, **2013**, 1, 18 | 7.3 | 44 |
| 270 | ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. *Acta Neuropathologica*, **2013**, 126, 443-51 | 14.3 | 239 |
| 269 | Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. *Acta Neuropathologica*, **2013**, 125, 891-900 | 14.3 | 144 |
| 268 | Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. *Acta Neuropathologica*, **2013**, 125, 651-8 | 14.3 | 247 |
| 267 | Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. *Acta Neuropathologica*, **2013**, 125, 351-8 | 14.3 | 158 |
| 266 | BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. *International Journal of Cancer*, **2013**, 133, 1624-30 | 7.5 | 81 |
| 265 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathologica*, **2013**, 126, 907-15 | 14.3 | 211 |
| 264 | AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. *Acta Neuropathologica*, **2013**, 126, 757-62 | 14.3 | 69 |
| 263 | Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72 | 24.3 | 478 |
| 262 | The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. *Cancer Research*, **2013**, 73, 3225-34 | 10.1 | 90 |
| 261 | Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. *Journal of Neuroimmunology*, **2013**, 265, 106-16 | 3.5 | 67 |

| | | | |
|---|---|---|---|
| 260 | Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. *Neurology*, **2013**, 81, 1515-22 | 6.5 | 160 |
| 259 | Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. *Journal of the National Cancer Institute*, **2013**, 105, 917-9 | 9.7 | 72 |
| 258 | Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. *Cell Cycle*, **2013**, 12, 1637-8 | 4.9 | 106 |
| 257 | Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. *Human Pathology*, **2013**, 44, 329-35 | 3.7 | 72 |
| 256 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29 | 14.3 | 115 |
| 255 | ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. *Lung Cancer*, **2013**, 80, 278-83 | 5.9 | 50 |
| 254 | Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. *Journal of Molecular Diagnostics*, **2013**, 15, 94-100 | 5.1 | 129 |
| 253 | Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. *Translational Oncology*, **2013**, 6, 685-96 | 4.9 | 20 |
| 252 | Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. *Apoptosis: an International Journal on Programmed Cell Death*, **2013**, 18, 1416-1425 | 5.4 | 50 |
| 251 | Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. *Neuro-Oncology*, **2013**, 15, 1405-12 | 1 | 45 |
| 250 | Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. *Journal of Investigative Dermatology*, **2013**, 133, 1372-5 | 4.3 | 5 |
| 249 | No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 426-30 | 1.9 | 8 |
| 248 | BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. *American Journal of Surgical Pathology*, **2013**, 37, 1592-602 | 6.7 | 112 |
| 247 | Expression of BRAF V600E mutant protein in epithelial ovarian tumors. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 159-64 | 1.9 | 25 |
| 246 | Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. *Clinical Cancer Research*, **2013**, 19, 5146-57 | 12.9 | 120 |
| 245 | Targeting the BRAF V600E mutation in multiple myeloma. *Cancer Discovery*, **2013**, 3, 862-9 | 24.4 | 176 |
| 244 | Protein kinase C□as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 14735-40 | 11.5 | 41 |
| 243 | Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. *American Journal of Surgical Pathology*, **2013**, 37, 193-9 | 6.7 | 74 |

| | | | |
|---|---|---|---|
| 242 | Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *American Journal of Surgical Pathology*, **2013**, 37, 61-5 | 6.7 | 254 |
| 241 | Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. *Brain Pathology*, **2013**, 23, 311-8 | 6 | 19 |
| 240 | Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. *American Journal of Surgical Pathology*, **2013**, 37, 413-20 | 6.7 | 88 |
| 239 | Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. *PLoS ONE*, **2013**, 8, e57152 | 3.7 | 20 |
| 238 | A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. *PLoS ONE*, **2013**, 8, e59773 | 3.7 | 34 |
| 237 | Nbn and atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye. *PLoS ONE*, **2013**, 8, e69209 | 3.7 | 13 |
| 236 | The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. *EMBO Molecular Medicine*, **2012**, 4, 38-51 | 12 | 69 |
| 235 | Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. *Acta Neuropathologica*, **2012**, 123, 223-33 | 14.3 | 178 |
| 234 | Brain metastases: pathobiology and emerging targeted therapies. *Acta Neuropathologica*, **2012**, 123, 205-22 | 14.3 | 133 |
| 233 | High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*, **2012**, 120, 2700-3 | 2.2 | 469 |
| 232 | Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. *International Journal of Oncology*, **2012**, 40, 2058-62 | 4.4 | 19 |
| 231 | Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. *Acta Neuropathologica*, **2012**, 124, 883-91 | 14.3 | 48 |
| 230 | BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. *Blood*, **2012**, 120, e28-34 | 2.2 | 172 |
| 229 | K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathologica*, **2012**, 124, 439-47 | 14.3 | 629 |
| 228 | LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathologica*, **2012**, 124, 875-81 | 14.3 | 87 |
| 227 | Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37 | 24.3 | 1243 |
| 226 | Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 859-64 | 4 | 107 |
| 225 | Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology. *Pathology Research and Practice*, **2012**, 208, 510-7 | 3.4 | 1 |

| | | | |
|---|---|---|---|
| 224 | IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. *Seizure: the Journal of the British Epilepsy Association*, **2012**, 21, 194-7 | 3.2 | 105 |
| 223 | Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71 | 56.2 | 600 |
| 222 | Nestin expression identifies ependymoma patients with poor outcome. *Brain Pathology*, **2012**, 22, 848-66 | 6 | 34 |
| 221 | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31 | 50.4 | 1655 |
| 220 | Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. *Journal of the American Academy of Dermatology*, **2012**, 67, 488-91 | 4.5 | 49 |
| 219 | Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. *PLoS ONE*, **2012**, 7, e41298 | 3.7 | 38 |
| 218 | Impaired Pten expression in human malignant peripheral nerve sheath tumours. *PLoS ONE*, **2012**, 7, e47595 | 3.7 | 33 |
| 217 | Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5 | 50.4 | 623 |
| 216 | 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. *International Journal of Cancer*, **2012**, 131, 766-8 | 7.5 | 70 |
| 215 | Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. *International Journal of Cancer*, **2012**, 131, 1963-8 | 7.5 | 17 |
| 214 | No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. *Journal of Neuro-Oncology*, **2012**, 109, 15-22 | 4.8 | 50 |
| 213 | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27 | 14.3 | 57 |
| 212 | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. *Acta Neuropathologica*, **2012**, 123, 841-52 | 14.3 | 68 |
| 211 | CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. *Acta Neuropathologica*, **2012**, 123, 853-60 | 14.3 | 116 |
| 210 | Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. *Brain Pathology*, **2012**, 22, 26-31 | 6 | 45 |
| 209 | Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. *EMBO Journal*, **2012**, 31, 2629-47 | 13 | 93 |
| 208 | Addressing diffuse glioma as a systemic brain disease with single-cell analysis. *Archives of Neurology* , **2012**, 69, 523-6 | | 93 |
| 207 | Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. *American Journal of Surgical Pathology*, **2012**, 36, 1796-800 | 6.7 | 114 |

| | | | |
|---|---|---|---|
| 206 | Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. *American Journal of Surgical Pathology*, **2012**, 36, 844-50 | 6.7 | 163 |
| 205 | Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma **2012**, | | 7 |
| 204 | Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. *PLoS ONE*, **2012**, 7, e33449 | 3.7 | 96 |
| 203 | Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. *PLoS ONE*, **2012**, 7, e47663 | 3.7 | 35 |
| 202 | Clinical neuropathology practice news 2-2012: BRAF V600E testing **2012**, 31, 64-6 | | 12 |
| 201 | BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. *Blood*, **2012**, 120, 4040-4040 | 2.2 | |
| 200 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature*, **2011**, 478, 197-203 | 50.4 | 1185 |
| 199 | Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 1415-21 | 4 | 46 |
| 198 | The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. *PLoS ONE*, **2011**, 6, e21065 | 3.7 | 31 |
| 197 | Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. *Histopathology*, **2011**, 58, 1167-72 | 7.3 | 12 |
| 196 | The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. *Brain Pathology*, **2011**, 21, 74-87 | 6 | 126 |
| 195 | Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57 | 24.3 | 395 |
| 194 | Identification of diagnostic serum protein profiles of glioblastoma patients. *Journal of Neuro-Oncology*, **2011**, 102, 71-80 | 4.8 | 40 |
| 193 | Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. *Journal of Neuro-Oncology*, **2011**, 105, 219-24 | 4.8 | 35 |
| 192 | Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. *Acta Neuropathologica*, **2011**, 121, 241-52 | 14.3 | 111 |
| 191 | R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. *Acta Neuropathologica*, **2011**, 121, 279-81 | 14.3 | 61 |
| 190 | Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 397-405 | 14.3 | 771 |
| 189 | Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 763-74 | 14.3 | 176 |

| | | | |
|---|---|---|---|
| 188 | Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. *Acta Neuropathologica*, **2011**, 122, 11-9 | 14.3 | 399 |
| 187 | A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. *Acta Neuropathologica*, **2011**, 122, 637-50 | 14.3 | 63 |
| 186 | Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. *Radiation Oncology*, **2011**, 6, 115 | 4.2 | 79 |
| 185 | Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. *Glia*, **2011**, 59, 1200-4 | 9 | 36 |
| 184 | Molecular signatures classify astrocytic gliomas by IDH1 mutation status. *International Journal of Cancer*, **2011**, 128, 1095-103 | 7.5 | 64 |
| 183 | Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. *International Journal of Cancer*, **2011**, 128, 1981-8 | 7.5 | 41 |
| 182 | Adult medulloblastoma comprises three major molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 2717-23 | 2.2 | 176 |
| 181 | Molecular markers in low-grade gliomas: predictive or prognostic?. *Clinical Cancer Research*, **2011**, 17, 4588-99 | 12.9 | 145 |
| 180 | FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. *Journal of Clinical Oncology*, **2011**, 29, 3852-61 | 2.2 | 125 |
| 179 | Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-□ *Clinical Cancer Research*, **2011**, 17, 4296-308 | 12.9 | 222 |
| 178 | The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. *European Journal of Cardio-thoracic Surgery*, **2011**, 39, 968-73 | 3 | 34 |
| 177 | PCR- and restriction endonuclease-based detection of IDH1 mutations. *Brain Pathology*, **2010**, 20, 298-306 | 6 | 53 |
| 176 | Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathology*, **2010**, 20, 245-54 | 6 | 410 |
| 175 | The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. *PLoS ONE*, **2010**, 5, e11858 | 3.7 | 23 |
| 174 | Defective p53 antiangiogenic signaling in glioblastoma. *Neuro-Oncology*, **2010**, 12, 894-907 | 1 | 14 |
| 173 | Molecular staging of intracranial ependymoma in children and adults. *Journal of Clinical Oncology*, **2010**, 28, 3182-90 | 2.2 | 177 |
| 172 | TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. *Journal of Clinical Oncology*, **2010**, 28, 5188-96 | 2.2 | 83 |
| 171 | Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. *Cancer Research*, **2010**, 70, 8003-14 | 10.1 | 61 |

| | | | |
|---|---|---|---|
| 170 | Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15553-8 | 11.5 | 210 |
| 169 | HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. *Clinical Cancer Research*, **2010**, 16, 3240-52 | 12.9 | 152 |
| 168 | Carbon ion radiation therapy for high-risk meningiomas. *Radiotherapy and Oncology*, **2010**, 95, 54-9 | 5.3 | 60 |
| 167 | Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. *Journal of Clinical Oncology*, **2010**, 28, 3054-60 | 2.2 | 109 |
| 166 | The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. *Oncology Research*, **2010**, 18, 469-80 | 4.8 | 14 |
| 165 | Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 729-36 | 3.1 | 66 |
| 164 | Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region. *Journal of Pediatric Hematology/Oncology*, **2010**, 32, 156-9 | 1.2 | 11 |
| 163 | Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. *American Journal of Surgical Pathology*, **2010**, 34, 1199-204 | 6.7 | 105 |
| 162 | IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. *Haematologica*, **2010**, 95, 1797-8 | 6.6 | 10 |
| 161 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 670-6 | 4 | 40 |
| 160 | Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. *Acta Neuropathologica*, **2010**, 120, 253-60 | 14.3 | 115 |
| 159 | Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. *Acta Neuropathologica*, **2010**, 120, 261-7 | 14.3 | 40 |
| 158 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathologica*, **2010**, 120, 707-18 | 14.3 | 596 |
| 157 | Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. *Journal of Neuro-Oncology*, **2010**, 98, 11-9 | 4.8 | 27 |
| 156 | Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. *European Journal of Haematology*, **2010**, 85, 457-9 | 3.8 | 34 |
| 155 | Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. *Leukemia Research*, **2010**, 34, 1091-3 | 2.7 | 15 |
| 154 | Histone deacetylase 8 in neuroblastoma tumorigenesis. *Clinical Cancer Research*, **2009**, 15, 91-9 | 12.9 | 278 |
| 153 | Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. *Neuro-Oncology*, **2009**, 11, 122-31 | 1 | 99 |

| | | | |
|---|---|---|---|
| 152 | Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. *Cancer Research*, **2009**, 69, 416-21 | 10.1 | 82 |
| 151 | Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. *Neuro-Oncology*, **2009**, 11, 803-18 | 1 | 32 |
| 150 | Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. *Clinical Cancer Research*, **2009**, 15, 5457-65 | 12.9 | 48 |
| 149 | Somatic mitochondrial mutations in pilocytic astrocytoma. *Cancer Genetics and Cytogenetics*, **2009**, 192, 30-5 | | 17 |
| 148 | Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. *Genes Chromosomes and Cancer*, **2009**, 48, 229-38 | 5 | 22 |
| 147 | Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. *Genes Chromosomes and Cancer*, **2009**, 48, 558-68 | 5 | 8 |
| 146 | Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica*, **2009**, 117, 457-64 | 14.3 | 91 |
| 145 | Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. *Acta Neuropathologica*, **2009**, 117, 445-56 | 14.3 | 82 |
| 144 | Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. *Acta Neuropathologica*, **2009**, 118, 401-5 | 14.3 | 223 |
| 143 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathologica*, **2009**, 118, 469-74 | 14.3 | 874 |
| 142 | Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathologica*, **2009**, 118, 599-601 | 14.3 | 330 |
| 141 | Gliomrezidiv?. *Onkopipeline*, **2009**, 2, 19-22 | | |
| 140 | Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. *Histopathology*, **2009**, 54, 241-7 | 7.3 | 4 |
| 139 | Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. *Modern Pathology*, **2009**, 22, 1263-71 | 9.8 | 11 |
| 138 | RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. *Brain Pathology*, **2009**, 19, 279-92 | 6 | 44 |
| 137 | Molecular pathology of oligodendroglial tumors. *Recent Results in Cancer Research*, **2009**, 171, 25-49 | 1.5 | 14 |
| 136 | Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. *Annals of Thoracic Surgery*, **2009**, 87, 379-84 | 2.7 | 18 |
| 135 | NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *Journal of Clinical Oncology*, **2009**, 27, 5874-80 | 2.2 | 625 |

| | | | |
|---|---|---|---|
| 134 | Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. *Journal of Clinical Oncology*, **2009**, 27, 5743-50 | 2.2 | 464 |
| 133 | The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. *Oncology Research*, **2009**, 18, 95-105 | 4.8 | 11 |
| 132 | Hereditary tumor syndromes and gliomas. *Recent Results in Cancer Research*, **2009**, 171, 83-102 | 1.5 | 35 |
| 131 | The evolution of our understanding on glioma. *Brain Pathology*, **2008**, 18, 455-63 | 6 | 20 |
| 130 | Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. *BMC Cancer*, **2008**, 8, 61 | 4.8 | 46 |
| 129 | Yes and PI3K bind CD95 to signal invasion of glioblastoma. *Cancer Cell*, **2008**, 13, 235-48 | 24.3 | 245 |
| 128 | The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. *Molecular Cancer Therapeutics*, **2008**, 7, 3566-74 | 6.1 | 77 |
| 127 | EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. *Neuro-Oncology*, **2008**, 10, 946-57 | 1 | 56 |
| 126 | Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. *Journal of Neuro-Oncology*, **2008**, 86, 23-30 | 4.8 | 11 |
| 125 | Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. *Journal of Molecular Histology*, **2008**, 39, 553-60 | 3.3 | 10 |
| 124 | Accumulation of genomic aberrations during clinical progression of medulloblastoma. *Acta Neuropathologica*, **2008**, 116, 383-90 | 14.3 | 22 |
| 123 | Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathologica*, **2008**, 116, 597-602 | 14.3 | 786 |
| 122 | MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. *Neoplasia*, **2007**, 9, 671-7 | 6.4 | 48 |
| 121 | DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. *Brain Pathology*, **2007**, 17, 363-70 | 6 | 45 |
| 120 | Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy. *Neuropathology*, **2007**, 27, 127-32 | 2 | 18 |
| 119 | Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. *Journal of Neuro-Oncology*, **2007**, 81, 53-60 | 4.8 | 533 |
| 118 | Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. *Journal of Neuro-Oncology*, **2007**, 82, 187-92 | 4.8 | 62 |
| 117 | Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. *Clinical and Experimental Metastasis*, **2007**, 24, 57-66 | 4.7 | 33 |

| | | | |
|---|---|---|---|
| 116 | A new clinico-pathological classification system for mesial temporal sclerosis. *Acta Neuropathologica*, **2007**, 113, 235-44 | 14.3 | 283 |
| 115 | Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. *Acta Neuropathologica*, **2007**, 113, 683-93 | 14.3 | 24 |
| 114 | Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. *Neuro-Oncology*, **2007**, 9, 291-7 | 1 | 40 |
| 113 | Long-term survival with glioblastoma multiforme. *Brain*, **2007**, 130, 2596-606 | 11.2 | 624 |
| 112 | Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. *Journal of Neurosurgery*, **2007**, 106, 633-7 | 3.2 | 23 |
| 111 | Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. *Clinical Cancer Research*, **2007**, 13, 6933-7 | 12.9 | 119 |
| 110 | Occurrence of a spinal anaplastic pilocytic astrocytoma and a supratentorial PNET in an adolescent. *Journal of Pediatric Hematology/Oncology*, **2007**, 29, 832-5 | 1.2 | 1 |
| 109 | Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. *Regulatory Peptides*, **2007**, 142, 52-9 | | 22 |
| 108 | Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. *Cancer Letters*, **2007**, 250, 107-16 | 9.9 | 42 |
| 107 | Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 428-32 | 8.8 | 80 |
| 106 | Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. *Cancer*, **2006**, 107, 1365-72 | 6.4 | 26 |
| 105 | Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. *International Journal of Cancer*, **2006**, 119, 792-800 | 7.5 | 60 |
| 104 | Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. *Carcinogenesis*, **2006**, 27, 664-71 | 4.6 | 76 |
| 103 | Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. *Journal of Neurotrauma*, **2006**, 23, 1518-28 | 5.4 | 99 |
| 102 | A role for beta-melanocyte-stimulating hormone in human body-weight regulation. *Cell Metabolism* , **2006**, 3, 141-6 | 24.6 | 149 |
| 101 | NF2 mutations in secretory and other rare variants of meningiomas. *Brain Pathology*, **2006**, 16, 15-9 | 6 | 50 |
| 100 | 45-year-old male with symptomatic mass in the frontal lobe. *Brain Pathology*, **2006**, 16, 89-90, 93 | 6 | 4 |
| 99 | The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. *Journal of Neuro-Oncology*, **2006**, 78, 7-14 | 4.8 | 354 |

| | | | |
|---|---|---|---|
| 98 | Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression **2005**, 27, 1029 | | 9 |
| 97 | Laser-assisted microdissection, techniques and applications in pathology (Review). *International Journal of Molecular Medicine*, **2005**, 15, 763 | 4.4 | 1 |
| 96 | Molecular genetic analysis of oligodendroglial tumors. *Journal of Neuropathology and Experimental Neurology*, **2005**, 64, 10-4 | 3.1 | 45 |
| 95 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. *Neoplasia*, **2005**, 7, 883-93 | 6.4 | 38 |
| 94 | Brain slice invasion model reveals genes differentially regulated in glioma invasion. *Biochemical and Biophysical Research Communications*, **2005**, 336, 1227-33 | 3.4 | 22 |
| 93 | Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. *American Journal of Pathology*, **2005**, 166, 1773-9 | 5.8 | 39 |
| 92 | Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. *Genes Chromosomes and Cancer*, **2005**, 44, 161-9 | 5 | 28 |
| 91 | Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas. *Acta Neuropathologica*, **2005**, 109, 314-20 | 14.3 | 9 |
| 90 | PIK3CA mutations in glioblastoma multiforme. *Acta Neuropathologica*, **2005**, 109, 639-42 | 14.3 | 70 |
| 89 | Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. *Acta Neuropathologica*, **2005**, 110, 306-11 | 14.3 | 20 |
| 88 | Alterations of cell cycle regulators in gliomatosis cerebri. *Journal of Neuro-Oncology*, **2005**, 72, 115-22 | 4.8 | 26 |
| 87 | Assessment of tumor cell invasion factors in gliomatosis cerebri. *Journal of Neuro-Oncology*, **2005**, 73, 109-15 | 4.8 | 12 |
| 86 | Estimating cancer survival and clinical outcome based on genetic tumor progression scores. *Bioinformatics*, **2005**, 21, 2438-46 | 7.2 | 41 |
| 85 | The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. *Journal of Perinatal Medicine*, **2005**, 33, 314-9 | 2.7 | 6 |
| 84 | Subclassification of nerve sheath tumors by gene expression profiling. *Brain Pathology*, **2004**, 14, 258-646 | | 37 |
| 83 | Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2004**, 107, 159-68 | 14.3 | 45 |
| 82 | Molecular pathogenesis of oligodendroglial tumors. *Journal of Neuro-Oncology*, **2004**, 70, 161-81 | 4.8 | 84 |
| 81 | Pathology and molecular genetics of oligodendroglial tumors. *Journal of Molecular Medicine*, **2004**, 82, 638-55 | 5.5 | 39 |

| | | | |
|---|---|---|---|
| 80 | Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. *Human Mutation*, **2004**, 23, 134-46 | 4.7 | 89 |
| 79 | Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. *International Journal of Cancer*, **2004**, 108, 839-44 | 7.5 | 25 |
| 78 | No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. *International Journal of Cancer*, **2004**, 109, 476-9 | 7.5 | 28 |
| 77 | Pdgfr-alpha in 1p/19q LOH oligodendrogliomas. *International Journal of Cancer*, **2004**, 112, 1081-2 | 7.5 | 9 |
| 76 | Differential concentration-dependent effects of prolonged norepinephrine infusion on intraparenchymal hemorrhage and cortical contusion in brain-injured rats. *Journal of Neurotrauma*, **2003**, 20, 1327-37 | 5.4 | 3 |
| 75 | Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review) **2003**, 23, 857 | | 1 |
| 74 | Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. *Journal of Neuro-Oncology*, **2003**, 65, 107-18 | 4.8 | 49 |
| 73 | Analysis of TP53 and PTEN in gliomatosis cerebri. *Acta Neuropathologica*, **2003**, 105, 529-36 | 14.3 | 28 |
| 72 | Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. *International Journal of Cancer*, **2003**, 106, 74-7 | 7.5 | 17 |
| 71 | No preferential loss of paternal 19q alleles in oligodendroglial tumors. *Annals of Neurology*, **2003**, 54, 256-8 | 9.4 | 9 |
| 70 | Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. *Cancer Research*, **2003**, 63, 1602-7 | 10.1 | 537 |
| 69 | The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. *Genes Chromosomes and Cancer*, **2002**, 35, 242-55 | 5 | 36 |
| 68 | Rare mutations of the DMBT1 gene in human astrocytic gliomas. *Oncogene*, **2002**, 21, 5956-9 | 9.2 | 23 |
| 67 | Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 1092-9 | 3.1 | 48 |
| 66 | Impact of genotype and morphology on the prognosis of glioblastoma. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 321-8 | 3.1 | 151 |
| 65 | Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. *American Journal of Pathology*, **2002**, 161, 313-9 | 5.8 | 157 |
| 64 | Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. *Neuroscience Letters*, **2002**, 324, 105-8 | 3.3 | 110 |
| 63 | Clonal analysis in glioblastoma with epithelial differentiation. *Brain Pathology*, **2001**, 11, 39-43 | 6 | 19 |

| | | | |
|---|---|---|---|
| 62 | Mutational analysis of INI1 in sporadic human brain tumors. *Acta Neuropathologica*, **2001**, 101, 479-82 | 14.3 | 30 |
| 61 | Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. *Acta Neuropathologica*, **2001**, 102, 69-74 | 14.3 | 46 |
| 60 | Analysis of the TSC2 gene in human medulloblastoma. *Acta Neuropathologica*, **2001**, 102, 380-4 | 14.3 | 6 |
| 59 | Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. *Journal of Pathology*, **2001**, 194, 81-7 | 9.4 | 50 |
| 58 | Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. *International Journal of Cancer*, **2001**, 94, 218-21 | 7.5 | 72 |
| 57 | Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. *Glia*, **2001**, 35, 167-79 | 9 | 103 |
| 56 | TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. *Journal of Neuro-Oncology*, **2001**, 52, 263-72 | 4.8 | 30 |
| 55 | Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. *Human Genetics*, **2001**, 108, 409-15 | 6.3 | 14 |
| 54 | Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 917-20 | 3.1 | 97 |
| 53 | Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report. *Journal of Neurosurgery*, **2001**, 95, 138-42 | 3.2 | 47 |
| 52 | Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. *Brain Pathology*, **2000**, 10, 85-92 | 6 | 65 |
| 51 | Chromosomal imbalances in brain metastases of solid tumors. *Brain Pathology*, **2000**, 10, 395-401 | 6 | 50 |
| 50 | Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25 | 5 | 11 |
| 49 | Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. *Human Genetics*, **2000**, 107, 350-6 | 6.3 | 36 |
| 48 | Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. *Journal of Neurology*, **2000**, 247, 455-60 | 5.5 | 51 |
| 47 | Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 544-58 | 3.1 | 114 |
| 46 | Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. *Journal of Neurosurgery*, **2000**, 92, 983-90 | 3.2 | 112 |
| 45 | Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25 | 5 | 70 |

| | | | |
|---|---|---|---|
| 44 | Clonal origin of recurrent meningiomas. *Brain Pathology*, **1999**, 9, 645-50 | 6 | 14 |
| 43 | A case history of glioma progression. *Acta Neuropathologica*, **1999**, 97, 525-32 | 14.3 | 22 |
| 42 | Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. *Acta Neuropathologica*, **1999**, 97, 547-51 | 14.3 | 5 |
| 41 | Analysis of the MEN1 gene in sporadic pituitary adenomas. *Journal of Pathology*, **1999**, 188, 168-73 | 9.4 | 25 |
| 40 | Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. *American Journal of Pathology*, **1999**, 155, 627-32 | 5.8 | 202 |
| 39 | Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 606-12 | 3.1 | 75 |
| 38 | Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 881-5 | 3.1 | 51 |
| 37 | Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 40-5 | 3.1 | 10 |
| 36 | Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. *Neuropathology*, **1998**, 18, 145-153 | 2 | 2 |
| 35 | PTEN mutations in gliomas and glioneuronal tumors. *Oncogene*, **1998**, 16, 2259-64 | 9.2 | 267 |
| 34 | A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. *Oncogene*, **1998**, 16, 2403-6 | 9.2 | 84 |
| 33 | Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. *International Journal of Cancer*, **1998**, 78, 306-9 | 7.5 | 31 |
| 32 | Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. *International Journal of Cancer*, **1998**, 79, 640-4 | 7.5 | 130 |
| 31 | Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, **1998**, 248, 314-5 | 5.1 | 1 |
| 30 | A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes. *Brain Pathology*, **1998**, 8, 13-8 | 6 | 35 |
| 29 | Clonality of multiple meningiomas. *Journal of Neurosurgery*, **1997**, 86, 853-8 | 3.2 | 62 |
| 28 | p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. *Cellular Physiology and Biochemistry*, **1997**, 7, 304-311 | 3.9 | 6 |
| 27 | Molecular genetic evidence for subtypes of oligoastrocytomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 1098-104 | 3.1 | 185 |

| | | | |
|---|---|---|---|
| 26 | A Novel Splice Site Associated Polymorphism in the Tuberous Sclerosis 2 (TSC2) Gene May Predispose to the Development of Sporadic Gangliogliomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 806-810 | 3.1 | 24 |
| 25 | Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. *Oncogene*, **1997**, 14, 611-6 | 9.2 | 96 |
| 24 | DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. *Nature Genetics*, **1997**, 17, 32-9 | 36.3 | 386 |
| 23 | Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. *Acta Neuropathologica*, **1997**, 93, 93-6 | 14.3 | 22 |
| 22 | Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. *International Journal of Cancer*, **1997**, 74, 322-5 | 7.5 | 19 |
| 21 | A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors. *Diagnostic Molecular Pathology*, **1996**, 5, 147-50 | | 26 |
| 20 | Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. *Journal of Neurosurgery*, **1996**, 85, 634-41 | 3.2 | 59 |
| 19 | The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. *Cancer Genetics and Cytogenetics*, **1996**, 88, 136-40 | | 50 |
| 18 | A Model for the Molecular Pathogenesis of Astrocytic Gliomas **1996**, 173-186 | | |
| 17 | Hereditary tumor syndromes of the nervous system: overview and rare syndromes. *Brain Pathology*, **1995**, 5, 145-51 | 6 | 48 |
| 16 | Evidence for subarachnoid spread in the development of multiple meningiomas. *Brain Pathology*, **1995**, 5, 11-4 | 6 | 28 |
| 15 | Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 91-5 | 3.1 | 266 |
| 14 | Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 622-6 | 3.1 | 35 |
| 13 | Molecular pathways in the formation of gliomas. *Glia*, **1995**, 15, 328-38 | 9 | 209 |
| 12 | MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. *Human Molecular Genetics*, **1994**, 3, 1841-5 | 5.6 | 83 |
| 11 | Deletion mapping of chromosome 19 in human gliomas. *International Journal of Cancer*, **1994**, 57, 676-80 | 7.5 | 79 |
| 10 | The retinoblastoma gene is involved in malignant progression of astrocytomas. *Annals of Neurology* , **1994**, 36, 714-21 | 9.4 | 193 |
| 9 | Subsets of glioblastoma multiforme defined by molecular genetic analysis. *Brain Pathology*, **1993**, 3, 19-26 | 6 | 520 |

| | | | |
|---|---|---|---|
| 8 | Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. *Journal of Neuropathology and Experimental Neurology*, **1993**, 52, 507-15 | 3.1 | 86 |
| 7 | Comparative study of p53 gene and protein alterations in human astrocytic tumors. *Journal of Neuropathology and Experimental Neurology*, **1993**, 52, 31-8 | 3.1 | 178 |
| 6 | Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. *Acta Neuropathologica*, **1993**, 86, 81-5 | 14.3 | 86 |
| 5 | Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. *Journal of Neurosurgery*, **1992**, 77, 295-301 | 3.2 | 158 |
| 4 | Central neurocytoma: histopathological variants and therapeutic approaches. *Journal of Neurosurgery*, **1992**, 76, 32-7 | 3.2 | 178 |
| 3 | Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. *Human Pathology*, **1992**, 23, 1402-9 | 3.7 | 64 |
| 2 | Location of N-methyl-N'-nitro-N-nitrosoguanidine-induced gastrointestinal tumors correlates with thiol distribution. *Carcinogenesis*, **1983**, 4, 879-83 | 4.6 | 35 |
| 1 | Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion | | 2 |